Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) EBT (2021 - 2025)

Verrica Pharmaceuticals has reported EBT over the past 5 years, most recently at -$8.3 million for Q4 2025.

  • Quarterly results put EBT at -$8.3 million for Q4 2025, up 38.76% from a year ago — trailing twelve months through Dec 2025 was -$19.0 million (up 74.3% YoY), and the annual figure for FY2025 was -$19.0 million, up 74.3%.
  • EBT for Q4 2025 was -$8.3 million at Verrica Pharmaceuticals, down from -$308000.0 in the prior quarter.
  • Over the last five years, EBT for VRCA hit a ceiling of $1.5 million in Q3 2022 and a floor of -$24.8 million in Q3 2023.
  • Median EBT over the past 5 years was -$10.1 million (2022), compared with a mean of -$10.9 million.
  • Biggest five-year swings in EBT: skyrocketed 111.81% in 2022 and later plummeted 1733.8% in 2023.
  • Verrica Pharmaceuticals' EBT stood at -$9.5 million in 2021, then surged by 37.89% to -$5.9 million in 2022, then plummeted by 316.02% to -$24.6 million in 2023, then surged by 45.01% to -$13.6 million in 2024, then skyrocketed by 38.76% to -$8.3 million in 2025.
  • The last three reported values for EBT were -$8.3 million (Q4 2025), -$308000.0 (Q3 2025), and -$393000.0 (Q2 2025) per Business Quant data.